Surprisingly, KIF5B-RET accounted for only 8.1% of total translocation events in baseline EGFR-mutated NSCLC patients resistant to EGFR-TKIs, whereas CCDC6-RET was identified in 47.3% of translocations events, ranking as the predominant RET fusion variant in acquired RET+ patients (Fig. 2d). This evidence concerns the gene KIF5B and non-small cell lung carcinoma.